MX2019001896A - Anticuerpo anti-pd-l1. - Google Patents

Anticuerpo anti-pd-l1.

Info

Publication number
MX2019001896A
MX2019001896A MX2019001896A MX2019001896A MX2019001896A MX 2019001896 A MX2019001896 A MX 2019001896A MX 2019001896 A MX2019001896 A MX 2019001896A MX 2019001896 A MX2019001896 A MX 2019001896A MX 2019001896 A MX2019001896 A MX 2019001896A
Authority
MX
Mexico
Prior art keywords
chain
antibody
amino acid
acid sequence
seq
Prior art date
Application number
MX2019001896A
Other languages
English (en)
Inventor
Konnai Satoru
Ohashi Kazuhiko
Murata Shiro
Okagawa Tomohiro
Nishimori Asami
Suzuki Yasuhiko
Nakajima Chie
Maekawa Naoya
Original Assignee
Univ Hokkaido Nat Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hokkaido Nat Univ Corp filed Critical Univ Hokkaido Nat Univ Corp
Publication of MX2019001896A publication Critical patent/MX2019001896A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona un anticuerpo anti-PD-L1 capaz de administración repetida incluso a animales que no sean rata. Un anticuerpo anti-PD-L1 que comprende (a) una cadena ligera que comprende una región variable de la cadena ligera que contiene CDR1 que tiene la secuencia de aminoácidos de QSLLYSENQKDY (SEQ ID NO: 37), CDR2 que tiene la secuencia de aminoácidos de WAT y CDR3 que tiene el amino secuencia ácida de GQYLVYPFT (SEQ ID NO: 38) y la región constante de la cadena ligera de un anticuerpo de un animal que no es rata; y (b) una cadena pesada que comprende una región variable de la cadena pesada que contiene CDR1 que tiene la secuencia de aminoácidos de GYTFTSNF (SEQ ID NO: 39), CDR2 que tiene la secuencia de aminoácidos de IYPEYGNT (SEQ ID NO: 40) y CDR3 que tiene el amino secuencia ácida de ASEEAVISLVY (SEQ ID NO: 41) y la región constante de la cadena pesada de un anticuerpo de un animal que no es rata. Una composición farmacéutica que comprende el anticuerpo anti-PD-L1 anterior como ingrediente activo. También se proporciona un método para preparar el anticuerpo anti-PD-L1 anterior.
MX2019001896A 2016-08-15 2017-08-10 Anticuerpo anti-pd-l1. MX2019001896A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2016159089 2016-08-15
JP2016159088 2016-08-15
JP2017061454 2017-03-27
JP2017110723 2017-06-05
PCT/JP2017/029055 WO2018034225A1 (ja) 2016-08-15 2017-08-10 抗ｐｄ－ｌ１抗体

Publications (1)

Publication Number Publication Date
MX2019001896A true MX2019001896A (es) 2019-08-29

Family

ID=61196830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001896A MX2019001896A (es) 2016-08-15 2017-08-10 Anticuerpo anti-pd-l1.

Country Status (13)

Country Link
US (2) US11312773B2 (es)
EP (1) EP3498838A4 (es)
JP (1) JP6960634B2 (es)
KR (2) KR102569068B1 (es)
CN (1) CN109790533B (es)
AU (1) AU2017313494B2 (es)
BR (1) BR112019002852A2 (es)
CA (1) CA3033896A1 (es)
MX (1) MX2019001896A (es)
PH (1) PH12019500319A1 (es)
RU (1) RU2744862C2 (es)
SG (1) SG11201901317TA (es)
WO (1) WO2018034225A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3033896A1 (en) * 2016-08-15 2018-02-22 National University Corporation Hokkaido University Anti-pd-l1 antibody
WO2019017420A1 (ja) 2017-07-20 2019-01-24 国立大学法人北海道大学 Ｐｄ－１／ｐｄ－ｌ１を標的とする阻害薬とｃｏｘ－２阻害薬との併用
CN111018989B (zh) * 2019-12-16 2021-03-23 郑州大学 一种抗pd-l1单克隆抗体以及在制备抗癌药物方面的应用
WO2024085686A1 (ko) * 2022-10-19 2024-04-25 충남대학교 산학협력단 구제역 바이러스 O형 캡시드 단백질 유래 단백질 및 sFc 단백질을 포함하는 재조합 단백질 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2811102B2 (ja) * 1989-12-28 1998-10-15 財団法人化学及血清療法研究所 ネコ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×ネコキメラ抗体
JP2837240B2 (ja) * 1990-06-07 1998-12-14 財団法人化学及血清療法研究所 イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体
AU640397B2 (en) * 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
CN101248089A (zh) * 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
EP3663314A1 (en) * 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US9617334B2 (en) * 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
US9644021B2 (en) 2013-01-11 2017-05-09 The California Institute For Biomedical Research Bovine fusion antibodies
CN105745225A (zh) * 2013-09-05 2016-07-06 杜克大学 Nav1.7抗体和使用所述抗体的方法
RU2535629C1 (ru) 2013-11-12 2014-12-20 Дмитрий Андреевич Соколов Элемент конструктора (варианты) и конструктор
DK3083694T3 (da) * 2013-12-20 2024-01-29 Intervet Int Bv Caniniserede, murine anti-canin-pd-1-antistoffer
EP3201230B1 (en) * 2014-09-30 2020-12-23 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
CA3039177A1 (en) * 2015-10-05 2017-04-13 Circle33 Llc Antibodies with improved stability to intestinal digestion
CA3033896A1 (en) * 2016-08-15 2018-02-22 National University Corporation Hokkaido University Anti-pd-l1 antibody

Also Published As

Publication number Publication date
WO2018034225A1 (ja) 2018-02-22
US20220227871A1 (en) 2022-07-21
RU2019105697A3 (es) 2020-09-17
PH12019500319A1 (en) 2019-10-21
AU2017313494B2 (en) 2023-09-21
SG11201901317TA (en) 2019-03-28
US11312773B2 (en) 2022-04-26
BR112019002852A2 (pt) 2019-06-25
KR102569068B1 (ko) 2023-08-21
RU2019105697A (ru) 2020-09-17
US20210277124A1 (en) 2021-09-09
AU2017313494A1 (en) 2019-03-07
EP3498838A4 (en) 2020-01-08
EP3498838A1 (en) 2019-06-19
KR20230125085A (ko) 2023-08-28
CN109790533B (zh) 2023-04-04
KR20190039256A (ko) 2019-04-10
RU2744862C2 (ru) 2021-03-16
JPWO2018034225A1 (ja) 2019-06-20
CN109790533A (zh) 2019-05-21
JP6960634B2 (ja) 2021-11-05
CA3033896A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
MX2019001897A (es) Anticuerpo anti-lag-3.
PH12019500319A1 (en) Anti-pd-l1 antibody
CO2019007844A2 (es) Anticuerpo anti-receptor de transferrina humana novedoso capaz de penetrar la barrera hematoencefálica
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
MX2019001841A (es) Anticuerpo anti-pd-1.
PE20142407A1 (es) Formulacion de anticuerpos
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20150945A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
PE20191135A1 (es) Anticuerpos antitau y metodos de uso
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
PE20141693A1 (es) Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
NZ626520A (en) Anti-lrp5 antibodies and methods of use
MX2019000641A (es) Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
MX2017005987A (es) Anticuerpos anti-interleucina(il)-1beta y metodos de uso.
MX2019007347A (es) Anticuerpo anti-cd3 y moleculas que comprenden el anticuerpo.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2022013566A (es) Anticuerpo.
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
MX2020009275A (es) Composiciones de anticuerpo anti-pd-1.
MY195550A (en) Antibody Formulation
MX2020010834A (es) Formulacion solida de mezclas insecticidas.